Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357989 · ClinicalTrials.gov registry record · Phase 3
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
A Phase 3 study, sponsored by Annovis Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 523
- Enrollment target
NCT05357989: Completed Phase 3 study, sponsored by Annovis Bio.
NCT05357989 is a Phase 3 study that has completed, run by Annovis Bio. The registered enrollment target is 523 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357989, a Phase 3 study, has completed, sponsored by Annovis Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 523 participants
- Enrollment target
Study Summary
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: * The study duration will be up to 7-8 months. * The double-blind treatment duration will be up to 6 months. * There will be 5 in-clinic visits and 7 phone calls
Primary Outcome
Change in the Score from the MDS- Unified Parkinson's Disease Rating Scale (UPDRS) Parts II from Baseline to the End of Trial. MDS-UPDRS Part II (Motor experiences of daily living) has 13 items and the score ranges from 0-52, with higher scores reflecting greater severity.
Interventions
- DRUG Placebo
- DRUG buntanetap/posiphen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 523 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2023-12-04 |
| Phase | Phase 3 |
What the finished NCT05357989 record still lists
NCT05357989 is an interventional study that assigns participants to a tested intervention. The registered 523 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05357989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05357989 about?
NCT05357989 is a clinical study titled "A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD". The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: * The study duration will be up to 7-8 months. * The double-blind treatment duration will be up to 6 months. * There will...
What is the current status of trial NCT05357989?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 523 participants. The study started on 2022-08-03. Estimated completion is 2023-12-04.
What interventions are being tested in trial NCT05357989?
The interventions under investigation include: Placebo (DRUG), buntanetap/posiphen (DRUG).
Who is sponsoring clinical trial NCT05357989?
This trial is sponsored by Annovis Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05357989's enrollment target sits among peer trials
523 716th of 2000 higher than 1,285 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI